Celldex Operating Income from 2010 to 2026

CLDX Stock

USD 25.67 1.71 6.25%

Celldex Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2026. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Celldex Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

1985-09-30

Previous Quarter

-63.9 M

Current Value

-73.6 M

Quarterly Volatility

18.1 M

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 5.8 M or Selling General Administrative of 42.1 M, as well as many indicators such as Price To Sales Ratio of 219, Dividend Yield of 0.0 or PTB Ratio of 2.38. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.

Build AI portfolio with Celldex Stock

Check out the analysis of Celldex Therapeutics Correlation against competitors.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Celldex Therapeutics over the last few years. Operating Income is the amount of profit realized from Celldex Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Celldex Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Celldex Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Celldex Operating Income Regression Statistics

	Arithmetic Mean	(108,500,699)
	Coefficient Of Variation	(49.64)
	Mean Deviation	45,301,047
	Median	(121,527,000)
	Standard Deviation	53,862,824
	Sample Variance	2901.2T
	Range	193.2M
	R-Value	(0.69)
	Mean Square Error	1601.8T
	R-Squared	0.48
	Significance	0
	Slope	(7,408,186)
	Total Sum of Squares	46419.3T

Celldex Operating Income History

	2026	-166.8 M
	2025	-175.6 M
	2024	-195.1 M
	2023	-154.5 M
	2022	-115.2 M
	2021	-71.2 M
	2020	-63.4 M

Other Fundumenentals of Celldex Therapeutics

Non Operating Income Net Other

Celldex Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Short Term Debt	Common Stock	Intangible Assets	Current Deferred Revenue	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		1.0	-0.09	-0.73	0.2	0.99	0.03	0.83	-0.33	0.13	-0.02	0.27	0.13	0.97	0.8	-0.47	0.63	0.5	0.94	-0.73	0.94	0.78
Total Stockholder Equity	1.0		-0.09	-0.73	0.12	1.0	0.01	0.84	-0.38	0.07	-0.1	0.25	0.07	0.98	0.82	-0.45	0.64	0.46	0.95	-0.73	0.96	0.8
Net Debt	-0.09	-0.09		-0.13	-0.08	-0.08	0.02	-0.1	0.1	-0.39	0.05	-0.54	-0.43	0.05	-0.18	0.33	0.01	0.12	0.1	-0.11	0.13	0.14
Retained Earnings	-0.73	-0.73	-0.13		-0.12	-0.72	-0.39	-0.66	0.41	0.22	-0.17	0.01	0.11	-0.73	-0.71	0.61	-0.93	-0.71	-0.62	0.37	-0.71	-0.84
Total Liab	0.2	0.12	-0.08	-0.12		0.05	0.25	0.1	0.44	0.72	0.82	0.35	0.72	0.03	-0.1	-0.34	0.17	0.51	0.0	0.06	-0.04	-0.09
Total Current Assets	0.99	1.0	-0.08	-0.72	0.05		-0.01	0.84	-0.43	0.01	-0.18	0.24	0.03	0.99	0.84	-0.42	0.62	0.4	0.96	-0.73	0.96	0.82
Net Receivables	0.03	0.01	0.02	-0.39	0.25	-0.01		0.15	0.02	-0.05	0.4	-0.19	0.05	-0.01	-0.01	-0.28	0.36	0.45	-0.09	0.07	-0.03	0.11
Accounts Payable	0.83	0.84	-0.1	-0.66	0.1	0.84	0.15		-0.43	0.11	-0.12	0.31	0.15	0.82	0.72	-0.42	0.59	0.33	0.78	-0.58	0.78	0.71
Short Term Debt	-0.33	-0.38	0.1	0.41	0.44	-0.43	0.02	-0.43		0.34	0.51	0.14	0.43	-0.43	-0.58	0.1	-0.48	0.07	-0.39	0.11	-0.45	-0.64
Common Stock	0.13	0.07	-0.39	0.22	0.72	0.01	-0.05	0.11	0.34		0.37	0.67	0.79	-0.04	-0.03	-0.2	-0.13	0.21	-0.02	0.09	-0.12	-0.25
Intangible Assets	-0.02	-0.1	0.05	-0.17	0.82	-0.18	0.4	-0.12	0.51	0.37		-0.07	0.38	-0.18	-0.33	-0.32	0.18	0.6	-0.22	0.1	-0.21	-0.22
Current Deferred Revenue	0.27	0.25	-0.54	0.01	0.35	0.24	-0.19	0.31	0.14	0.67	-0.07		0.8	0.15	0.39	-0.38	0.06	0.0	0.1	0.05	0.03	0.0
Property Plant Equipment	0.13	0.07	-0.43	0.11	0.72	0.03	0.05	0.15	0.43	0.79	0.38	0.8		-0.05	0.06	-0.29	-0.06	0.12	-0.08	0.12	-0.16	-0.23
Short Term Investments	0.97	0.98	0.05	-0.73	0.03	0.99	-0.01	0.82	-0.43	-0.04	-0.18	0.15	-0.05		0.82	-0.37	0.62	0.41	0.98	-0.74	0.99	0.84
Net Tangible Assets	0.8	0.82	-0.18	-0.71	-0.1	0.84	-0.01	0.72	-0.58	-0.03	-0.33	0.39	0.06	0.82		-0.48	0.72	0.34	0.74	-0.47	0.78	0.8
Long Term Debt Total	-0.47	-0.45	0.33	0.61	-0.34	-0.42	-0.28	-0.42	0.1	-0.2	-0.32	-0.38	-0.29	-0.37	-0.48		-0.65	-0.52	-0.22	0.14	-0.27	-0.35
Capital Surpluse	0.63	0.64	0.01	-0.93	0.17	0.62	0.36	0.59	-0.48	-0.13	0.18	0.06	-0.06	0.62	0.72	-0.65		0.7	0.5	-0.17	0.6	0.83
Short Long Term Debt	0.5	0.46	0.12	-0.71	0.51	0.4	0.45	0.33	0.07	0.21	0.6	0.0	0.12	0.41	0.34	-0.52	0.7		0.33	-0.29	0.38	0.41
Net Invested Capital	0.94	0.95	0.1	-0.62	0.0	0.96	-0.09	0.78	-0.39	-0.02	-0.22	0.1	-0.08	0.98	0.74	-0.22	0.5	0.33		-0.77	0.99	0.8
Long Term Investments	-0.73	-0.73	-0.11	0.37	0.06	-0.73	0.07	-0.58	0.11	0.09	0.1	0.05	0.12	-0.74	-0.47	0.14	-0.17	-0.29	-0.77		-0.75	-0.41
Net Working Capital	0.94	0.96	0.13	-0.71	-0.04	0.96	-0.03	0.78	-0.45	-0.12	-0.21	0.03	-0.16	0.99	0.78	-0.27	0.6	0.38	0.99	-0.75		0.86
Capital Stock	0.78	0.8	0.14	-0.84	-0.09	0.82	0.11	0.71	-0.64	-0.25	-0.22	0.0	-0.23	0.84	0.8	-0.35	0.83	0.41	0.8	-0.41	0.86

Click cells to compare fundamentals

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-175.6 M	-166.8 M
Non Operating Income Net Other	580.8 K	551.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Celldex Operating Income from 2010 to 2026

Latest Celldex Therapeutics' Operating Income Growth Pattern

Celldex Operating Income Regression Statistics

Celldex Operating Income History

Other Fundumenentals of Celldex Therapeutics

Celldex Therapeutics Operating Income component correlations

About Celldex Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Celldex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY